Halogenated antituberculosis agents
AssigneeUniversity of the Sciences in Philadelphia
InventorsFarzad Kobarfard, Joel M. Kauffman
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversity of the Sciences in Philadelphia
InventorsFarzad Kobarfard, Joel M. Kauffman
Estimating the term…
Halogenated derivatives of two synthetic anti-tuberculosis agents, thioacetazone and p-aminosalicylic acid, have been synthesized. In general, the halogenated compound has the structure of Structure I: 1 wherein X1 is a halogen and X2 is a second halogen or hydrogen, and Y is sulfur or oxygen; or, has the structure of Structure IV: 2 wherein X1 is a halogen and X2 is a second halogen or hydrogen. Alternatively, the halogenated compounds may be pharmaceutically acceptable salts of these compounds. These halogenated derivatives possess anti-mycobacterial activity and are particularly useful for the treatment of Mycobacterium tuberculosis infections. In particular, fluorinated analogs of thioacetazone and p-amino-salicylic acid have been synthesized for use as anti-tuberculosis therapeutic agents either alone or in combination with other conventional anti-tuberculosis therapeutic agents.
A halogenated compound having Structure I or a pharmaceutically acceptable salt thereof:
A halogenated compound having Structure II:
A halogenated compound having Structure IV or a pharmaceutically acceptable salt thereof:
A halogenated compound having Structure III:
Dependencies are inferred from the claim text.